Sera Prognostics, Inc. (SERA)
USD 8.18
(-0.37%)
USD 8.18
(-0.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.28 Million USD | 12.47% |
| 2022 | -42.9 Million USD | -28.78% |
| 2021 | -33.6 Million USD | -100.2% |
| 2020 | -17.11 Million USD | -25.81% |
| 2019 | -13.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.86 Million USD | -2.25% |
| 2024 Q2 | -8.9 Million USD | -0.91% |
| 2023 Q1 | -10.54 Million USD | -8.44% |
| 2023 FY | - USD | 12.47% |
| 2023 Q3 | -7.19 Million USD | 33.91% |
| 2023 Q2 | -10.88 Million USD | -3.21% |
| 2023 Q4 | -8.53 Million USD | -18.62% |
| 2022 Q2 | -11.31 Million USD | 6.0% |
| 2022 Q1 | -12.03 Million USD | 3.55% |
| 2022 Q4 | -9.72 Million USD | 10.4% |
| 2022 FY | - USD | -28.78% |
| 2022 Q3 | -10.85 Million USD | 4.06% |
| 2021 Q2 | -8.25 Million USD | -41.07% |
| 2021 FY | - USD | -100.2% |
| 2021 Q4 | -12.48 Million USD | -34.45% |
| 2021 Q1 | -5.85 Million USD | -26.75% |
| 2021 Q3 | -9.28 Million USD | -12.48% |
| 2020 Q2 | -4.05 Million USD | -0.57% |
| 2020 Q1 | -4.03 Million USD | 0.0% |
| 2020 Q4 | -4.61 Million USD | -4.65% |
| 2020 FY | - USD | -25.81% |
| 2020 Q3 | -4.41 Million USD | -8.78% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 83.48% |
| Prenetics Global Limited | -47.89 Million USD | 26.326% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1991.701% |
| CareDx, Inc | -89.65 Million USD | 60.642% |
| Exact Sciences Corporation | 41.87 Million USD | 184.265% |
| Exagen Inc. | -19.15 Million USD | -84.237% |
| Inotiv, Inc. | -26.5 Million USD | -33.128% |
| Guardant Health, Inc. | -433.3 Million USD | 91.856% |
| Biodesix, Inc. | -37.1 Million USD | 4.894% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -1319.908% |
| Precipio, Inc. | -4.31 Million USD | -717.207% |
| iSpecimen Inc. | -9.1 Million USD | -287.611% |
| Natera, Inc. | -383.27 Million USD | 90.793% |
| Aspira Women's Health Inc. | -16.49 Million USD | -113.977% |
| Standard BioTools Inc. | -54.45 Million USD | 35.202% |
| 23andMe Holding Co. | -291.87 Million USD | 87.91% |
| Castle Biosciences, Inc. | -45.02 Million USD | 21.626% |
| Personalis, Inc. | -96.8 Million USD | 63.549% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 69.985% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -267.916% |
| OpGen, Inc. | -29.51 Million USD | -19.572% |
| T2 Biosystems, Inc. | -43.87 Million USD | 19.574% |
| Myriad Genetics, Inc. | -67.8 Million USD | 47.954% |
| ICON Public Limited Company | 1.63 Billion USD | 102.163% |
| NeoGenomics, Inc. | -17.6 Million USD | -100.415% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1991.701% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 102.898% |
| RadNet, Inc. | 292.78 Million USD | 112.052% |
| MDxHealth SA | -30.46 Million USD | -15.817% |
| Psychemedics Corporation | -251 Thousand USD | -13958.566% |
| Illumina, Inc. | -608 Million USD | 94.196% |
| Check-Cap Ltd. | -17.64 Million USD | -99.938% |
| Twist Bioscience Corporation | -176.7 Million USD | 80.031% |
| DarioHealth Corp. | -53.49 Million USD | 34.036% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 24.199% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -260.631% |
| OPKO Health, Inc. | -65.51 Million USD | 46.14% |
| Medpace Holdings, Inc. | 363.15 Million USD | 109.717% |
| Neogen Corporation | 182.59 Million USD | 119.325% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -300.501% |
| Prenetics Global Limited | -47.89 Million USD | 26.326% |
| Mainz Biomed B.V. | -25.01 Million USD | -41.085% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -362.519% |
| Trinity Biotech plc | -24.09 Million USD | -46.431% |
| Neuronetics, Inc. | -22.75 Million USD | -55.046% |
| Sotera Health Company | 514.14 Million USD | 106.863% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -362.519% |